Key result
Renal fibrosis acts as a final common pathway driving kidney disease progression and adverse outcomes.
Key points are not available for this paper at this time.
Design
Review
Renal fibrosis targeting should not yet change CKD practice; leaves open validation of specific mediators in cardiorenal trials.
Renal fibrosis is a key determinant of the progression of many renal diseases and represents a final common pathway that adversely affects outcome. The evolution of renal fibrosis is complicated and involves many cellular and molecular mediators. In this review we will outline the key players in the fibrotic response of the injured kidney and discuss emerging research in the field.
No takes yet. Share an insight, caveat, or question.
Conway et al. (2011) studied this question. Renal fibrosis serves as a complex final common pathway in the progression of many kidney diseases, driven by multiple cellular and molecular mediators that adversely affect outcomes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: